BACKGROUND: Surgical cytoreduction and intraperitoneal chemotherapy is increasingly accepted as an effective treatment modality for @entity2466 . For the majority of @entity1 with low-grade histology, outcomes have been encouraging. The survival of @entity1 with @entity5 of malignant character is protracted and this study was designed to evaluate the effectiveness of this surgical strategy on outcomes. METHODS: Forty-six consecutive @entity1 with mucinous and nonmucinous @entity5 with peritoneal dissemination were studied. Clinicopathological and treatment related factors were obtained from a prospective database. The study's end points of disease-free survival (DFS) and @entity1349 ( @entity1349 ) were analyzed using the Kaplan-Meier method. RESULTS: The median DFS and @entity1349 after cytoreduction were 20.5 and 56.4  months respectively. Five-year @entity1349 rate was 45%. Five independent factors associated with DFS and @entity1349 were identified through a multivariate analysis: age (DFS p  =  0.001, @entity1349 p  =  0.002), completeness of cytoreduction (DFS p  =  0.001, @entity1349 p  =  0.003), previous chemotherapy treatment (DFS p  =  0.021), CA 199 levels (DFS p  =  0.013), and @entity5 grade ( @entity1349 p  =  0.005). CONCLUSIONS: Cytoreductive surgery and intraperitoneal chemotherapy may achieve long-term survival in @entity5 with peritoneal dissemination for which the predictors of outcomes identified through this study may tailor the disease management to commit @entity1 early toward this successful surgical strategy.

Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'appendiceal cancer', 'appendiceal malignancies', 'neoplasms'] @entity2466 :: ('MESH:D001063', 'Disease') :: ['mucinous appendiceal neoplasm'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1 :: (9606,Species) :: ['patients']
